Risk and relative risk for heterozygotes to develop FMF.
- Isabelle Jéru (369567)
- Véronique Hentgen (430312)
- Emmanuelle Cochet (369569)
- Philippe Duquesnoy (65332)
- Gaëlle Le Borgne (430313)
- Emmanuel Grimprel (430314)
- Katia Stankovic Stojanovic (430315)
- Sonia Karabina (430316)
- Gilles Grateau (369571)
- Serge Amselem (65335)
View in ORKG Publication date
July 2013
DOIAbstract
<p>Considering the prevalence of FMF reported in Turks and Sephardic Jews <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0068431#pone.0068431-Samuels1" target="_blank">[25]</a>–<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0068431#pone.0068431-Ozen1" target="_blank">[26]</a>, as well as the distribution of <i>MEFV</i> genotypes in affected and healthy individuals, we could make a rough estimate of the risk and relative risk for heterozygotes to develop FMF, as compared to healthy individuals. Risks are indicated by labels next to each sector, relative risks are displayed below each genotype distribution. m: mutated <i>MEFV</i> allele; N: normal <i>MEFV</i> allele.</p